Food & Herbal Plant Extract Ingredient Manufacturer Malaysia.
Fresh ginger rhizome beside a small heap of dried ginger root powder on a laboratory bench
Fresh ginger rhizome and dried ginger root powder, with a review of the human trial evidence for ginger extract by outcome.
Evidence grade B27 PubMed records citedWritten by a registered pharmacistReviewed by Dr Yong Yi Yi

Author: Vitthia Rama Murti, Registered Pharmacist (RPh 15632)
Standardisation and specification content: co-signed by Ts. Ng Kuak Ping
Reviewed by: Dr Yong Yi Yi
Review date: 3 November 2026
Evidence grade: B
Commercial interest: Bionutricia has a commercial interest in this subject, because Bionutricia Extract sells Ginger (Zingiber officinale) Standardized Extract Powder. See the disclosure section.

Abstract

Background: Ginger (Zingiber officinale) extract has been tested in human trials on several outcomes, and the results differ by outcome.

Objective: To review what human trials of ginger extract report for nausea, osteoarthritis and joint pain, dysmenorrhoea and metabolic outcomes, outcome by outcome.

Methods: PubMed was searched on 3 November 2026 with six search strings, restricted to human clinical evidence. Abstracts were read and studies were included where they could inform the question.

Results: Twenty-seven records were included. For chemotherapy-induced nausea, a 2024 randomised trial (n=103; 84 mg/day gingerols and shogaols) reported results favouring ginger for nausea-related quality of life and delayed nausea severity. Pregnancy meta-analyses reported improved nausea versus placebo but no significant effect on vomiting. In knee osteoarthritis, a 2001 trial reported 63% versus 50% responders for knee pain on standing (P=0.048), whereas a 2012 trial of 1 g/day powdered ginger found no improvement in joint pain, and a 2020 meta-analysis judged the evidence insufficient. For dysmenorrhoea, meta-analyses reported reduced pain intensity versus placebo, while a 2017 trial found exercise significantly more effective than ginger for pain relief, and the 2016 Cochrane review of dietary supplements judged all the evidence low or very low quality. A 2019 meta-analysis of 14 trials reported lower body weight and fasting glucose, while a 2021 crossover trial of 5% gingerol capsules found that ginger did not increase the thermic effect of food.

Conclusion: Evidence grade B. Outcome-specific benefits appear in several trials, while negative results appear for other outcomes in the same areas, so the record does not support a consistent effect across outcomes.

Review methodology

Database: PubMed, searched through the clinical-study search with the human clinical evidence restriction on. Search date: 3 November 2026.

Search terms, verbatim:

  1. ginger Zingiber officinale extract standardized gingerols randomized controlled trial
  2. ginger extract gingerols shogaols human clinical trial
  3. ginger osteoarthritis knee pain randomized placebo
  4. ginger primary dysmenorrhea menstrual pain randomized trial
  5. ginger supplementation glycaemic control insulin resistance lipid randomized
  6. ginger nausea vomiting pregnancy or postoperative randomized trial

Included: human randomised trials (including crossover trials), and systematic reviews and meta-analyses of oral ginger in humans, where the abstract reports a result for one of the four outcome areas in the question (nausea, osteoarthritis and joint pain, dysmenorrhoea, metabolic outcomes).

Excluded, with the reason in each case:

  • PMID 30935515: the abstract describes “2000 mg/day dried ginger powder in 4 capsules” for ulcerative colitis. Its outcomes (oxidative stress, disease activity index, quality of life) fall outside the four outcome areas.
  • PMID 36453014: the abstract describes the product as “a combination of honey and ginger”, so the effect cannot be attributed to ginger alone.
  • PMID 38706368: the abstract covers “herbal interventions” for cardiovascular disease as a group and gives no ginger-specific result.
  • PMID 40077632: ginger is listed among “single-component extracts” in a review of herbal medicines for gingivitis and periodontitis, and the abstract reports no ginger-specific result.
  • PMID 40806131: a network meta-analysis of seven supplements in which the abstract states that “Curcumin, collagen, ginger, and krill oil also demonstrated benefits in some outcomes”, with no ginger-specific estimate.
  • PMID 35713447: the abstract states that “A randomized intervention clinical and controlled trial with a triple-blind design is described”; no outcome is reported.
  • PMID 29768938: the abstract gives “5% active ingredient”, and its migraine outcome falls outside the four outcome areas.
  • PMID 27701665: a review of treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy in which ginger is one of several agents, and its ginger finding is one item in a narrative list with no ginger-specific estimate.
  • PMID 37690779: the abstract reports gastrointestinal bacteria composition, gastrointestinal symptoms, mental health, fatigue and quality of life, outcomes that fall outside the four outcome areas.

How records were assessed: each included record was read from its PubMed abstract. Design, participant numbers, population, dose and form, duration and outcome were taken from the abstract’s own wording, and each figure is quoted as the abstract prints it.

Summary of study findings

Chemotherapy-induced nausea: PMID 37699474 (2024, randomised trial)

Design and population: parallel, double-blind, placebo-controlled randomised trial, 1:1 allocation, at two hospitals in Australia. 103 enrolled and analysed (ginger 52; placebo 51). Chemotherapy-naive adults scheduled for moderately to highly emetogenic chemotherapy.
Dose and form: “Four standardized ginger capsules (totaling 84 mg/day active gingerols/shogaols), or placebo”. Duration: from the day of chemotherapy for 5 days, cycles 1 through 3.
Outcome, abstract wording: “clinically relevant evidence against the null hypothesis, favoring ginger, in change scores for nausea-related QoL”, “delayed nausea severity” and “fatigue”. “There was no effect of ginger on anticipatory or acute CINV, health-related QoL, anxiety, or depression.” “No serious adverse events were reported.”

Chemotherapy-induced nausea and vomiting: PMID 30299420 (2019, meta-analysis of 10 randomised trials)

Design and population: meta-analysis of 10 randomised trials with complete data, English-language studies from 2000 to 2017, in patients who underwent chemotherapy. Dose: the abstract defines the intervention as “0.5 to 2.0 g/d” of ginger in the forms it lists, including ginger extract and 6-gingerol.
Outcome, abstract wording: “The odds ratio (OR) of ginger in controlling CINV was 0.71 (95% confidence interval [CI], 0.54-0.94; P = .015).” “ginger could only reduce acute CINV in patients (OR, 0.60; 95% CI, 0.42-0.86; P = .006)”. The abstract notes that heterogeneity existed among the samples.

Pregnancy-associated nausea: PMID 24642205 (2014, systematic review and meta-analysis)

Design and population: systematic review and meta-analysis of 12 randomised trials involving 1278 pregnant women.
Dose: “Subgroup analyses seemed to favor the lower daily dosage of <1500 mg ginger for nausea relief.”
Outcome, abstract wording: “Ginger significantly improved the symptoms of nausea when compared to placebo (MD 1.20, 95% CI 0.56-1.84, p = 0.0002, I² = 0%). Ginger did not significantly reduce the number of vomiting episodes during NVP, when compared to placebo”.

Pregnancy nausea and vomiting: PMID 31937153 (2022, meta-analysis)

Design and population: meta-analysis of 13 studies involving 1174 subjects, randomised trials of ginger for nausea and vomiting in pregnancy.
Outcome, abstract wording: compared with placebo, “ginger intervention has significant effect in improving general symptom of NVP [OR = 7.475, 95% CI = (4.133, 13.520), I2 = 30.1%], relieving severity of nausea [SMD = 0.821, 95% CI = (0.585, 1.056), I2 = 38.9%], but not significant in reducing vomiting [SMD = 0.549, 95% CI = (-0.268, 1.365), I2 = 91.4%]”. Compared with vitamin B6, “ginger intervention has no significant effect on improving general symptom of NVP”.

Nausea and vomiting in pregnancy, complementary medicine: PMID 36969661 (2023, systematic review and meta-analysis)

Design and population: systematic review and meta-analysis of 33 randomised trials of complementary and alternative medicine for nausea and vomiting in pregnancy. The ginger findings are reported separately.
Outcome, abstract wording for ginger: “Compared with placebo, ginger had a higher effective rate [RR = 1.68, 95% CI (1.09, 2.57), P = 0.018; Low-quality evidence], and lower Visual analog scale (VAS) of Nausea [WMD = -1.21, 95% CI (-2.34, -0.08), P = 0.036; Low-quality evidence].” The same abstract states that “Ginger had the same antiemetic effect as placebo [WMD = 0.05, 95% CI (-0.23, 0.32), P = 0.743; Low-quality evidence].”

Knee osteoarthritis: PMID 11710709 (2001, randomised trial)

Design and population: randomised, double-blind, placebo-controlled, multicentre, parallel-group study. 261 patients enrolled and 247 evaluable. Patients with knee osteoarthritis and moderate-to-severe pain.
Dose and form: “a standardized and highly concentrated extract of 2 ginger species, Zingiber officinale and Alpinia galanga (EV.EXT 77)”, taken twice daily.
Duration: 6 weeks.
Outcome, abstract wording: “The percentage of responders experiencing a reduction in ‘knee pain on standing’ was superior in the ginger extract group compared with the control group (63% versus 50%; P = 0.048).” The abstract also reports GI adverse events: “Patients receiving ginger extract experienced more gastrointestinal (GI) adverse events than did the placebo group (59 patients versus 21 patients).”

Knee and hip osteoarthritis, crossover: PMID 10607493 (2000, randomised crossover trial)

Design and population: randomised, placebo-controlled, cross-over, double-blind, double-dummy study with a one-week washout and three treatment periods of three weeks. Patients with osteoarthritis of the hip or knee.
Dose and form: “ginger extract”, against placebo and ibuprofen.
Outcome, abstract wording: “In the cross-over study, no significant difference between placebo and ginger extract could be demonstrated”. The abstract reports a better effect of ginger extract than placebo only “in the first treatment period” by explorative tests, and concludes that “a significant difference was not observed in the study as a whole.”

Powdered ginger, knee osteoarthritis: PMID 23964445 (2012, randomised trial)

Design and population: double-blind randomised controlled trial in patients with osteoarthritic knees. 30 participants in each group.
Dose and form: “one gram of powdered ginger per day in a capsule compared with a placebo”.
Duration: 8 weeks.
Outcome, abstract wording: “One gram of powdered ginger per day did not improve knee joint pain, symptoms, daily activities, sports activities and quality of life compared with a placebo. Prominent side effects did not occur.”

Gonarthritis, crossover: PMID 14609531 (2003, randomised crossover trial)

Design and population: double-blind, placebo-controlled crossover study of 6 months, with the crossover after 3 months. 29 patients randomised (6 men, 23 women) with symptomatic gonarthritis.
Dose and form: ginger extract (Zintona EC), “250 mg of Zingiberis Rhizoma per capsule, qid”.
Duration: 24 weeks, with 48-week follow-up.
Outcome, abstract wording: “Zintona EC was as effective as placebo during the first 3 months of the study, but at the end of 6 months, 3 months after crossover, the ginger extract group showed a significant superiority over the placebo group.”

Steamed ginger extract, mild knee osteoarthritis: PMID 39212491 (2024, randomised trial)

Design and population: double-blind, placebo-controlled randomised trial. 100 subjects randomised 1:1 with mild knee osteoarthritis.
Dose and form: “the GGE03 (0.48 g day-1 as GGE03) or placebo (0 g day-1 as GGE03) group”. The abstract describes the product as “steamed ginger extract (GGE03)”.
Duration: 12 weeks.
Outcome, abstract wording: “pain visual analog scale (VAS), Korean-Western Ontario and McMaster University Osteoarthritis Index (K-WOMAC; total scores, sub-scores) and patient global assessment (PGA) were found to be decreased in a statistically significantly manner in the GGE03 group compared to the placebo group. No significant changes were observed in any safety endpoint.”

Knee osteoarthritis, meta-analysis of 5 trials: PMID 25300574 (2015)

Design and population: meta-analysis of randomised placebo-controlled trials of oral ginger; five trials with 593 patients were analysed.
Outcome, abstract wording: “a statistically significant pain reduction SMD = -0.30 ([95% CI: [(-0.50, -0.09)], P = 0.005]) with a low degree of inconsistency among trials (I(2) = 27%), and a statistically significant reduction in disability SMD = -0.22 ([95% CI: ([-0.39, -0.04)]; P = 0.01; I(2) = 0%]), both in favor of ginger.” The abstract adds: “Patients given ginger were more than twice as likely to discontinue treatment compared to placebo ([RR = 2.33; 95% CI: (1.04, 5.22)]; P = 0.04; I(2) = 0%]).” The abstract states: “We judged the evidence to be of moderate quality”.

Knee osteoarthritis, systematic review and meta-analysis, 2020: PMID 32214292

Design and population: PRISMA systematic review with meta-analysis of randomised trials; seven trials met the criteria and four were included in the quantitative synthesis.
Outcome, abstract wording: “For the comparison capsules versus placebo, mean difference for pain was -7.88 mm; 95% confidence interval (CI), 11.92 to 3.85 (P = 0.00), and standard mean difference for knee function was -1.61 points; 95% CI, -4.30 to -1.09 (P = 0.24).” The abstract concludes: “There is insufficient evidence to support the use of oral ginger compared with placebo in the pain relief and function improvement in patients with knee osteoarthritis.” Its limitations state that “The current evidence is heterogeneous and has a poor methodologic quality.”

Joint pain and inflammatory markers: PMID 40732990 (2025, randomised trial)

Design and population: placebo-controlled, randomised, parallel-arm study. 30 men and women (56.0 ± 9.0 years) with a history of mild to severe joint and muscle pain and inflammation.
Dose and form: “125 mg/d of a placebo or ginger (standardized to contain 10% total gingerols and no more than 3% total shogaols)”. The abstract’s conclusion gives this as “providing 12.5 mg/d of gingerols”. It also describes the extract as one “obtained through supercritical CO2 extraction and subsequent fermentation”.
Duration: 58 days.
Outcome, abstract wording: “There was evidence that ginger supplementation attenuated perceptions of muscle pain in the vastus medialis; improved ratings of pain, stiffness, and functional capacity; and affected several inflammatory markers (e.g., IL-6, INF-ϒ, TNF-α, and C-Reactive Protein concentrations)”. The abstract also reports that “ginger supplementation increased eosinophils”.

Primary dysmenorrhoea, meta-analysis, 2024: PMID 38770631

Design and population: systematic review and meta-analysis; 24 studies in qualitative analysis and 12 in quantitative analysis, of ginger against placebo for primary dysmenorrhoea.
Outcome, abstract wording: “ginger is notably more effective than placebo in reducing both the intensity (SMD = -1.13; 95% CI = -1.59 to -0.68, I2 = 81.05%) and duration of pain (SMD = -0.29; 95% CI = -0.46 to -0.12).” The abstract reports “no differences between ginger and nonsteroidal anti-inflammatory drugs (NSAIDs)” for pain intensity, and that “Safety-related data were infrequently reported.”

Primary dysmenorrhoea, meta-analysis, 2015: PMID 26177393

Design and population: systematic review and meta-analysis of randomised trials; seven trials met the criteria and four placebo-controlled trials were included in the meta-analysis.
Dose: the conclusion refers to “750-2000 mg ginger powder during the first 3-4 days of menstrual cycle”.
Outcome, abstract wording: “a significant effect of ginger in reducing PVAS in subjects having primary dysmenorrhea (risk ratio, -1.85; 95% CI of -2.87, -0.84, P = 0.0003).” The abstract notes that “Six RCTs out of 7 exhibited low to moderate of risk of bias.”

Dysmenorrhoea, Cochrane review, 2016: PMID 27000311

Design and population: Cochrane systematic review; 27 randomised trials with 3101 women. Ginger (Zingiber officinale) is one of 12 herbal medicines included.
Outcome, abstract wording: “We judged all the evidence to be of low or very low quality.”

Primary dysmenorrhoea, meta-analysis of herbal medicine, 2020: PMID 32603204

Design and population: systematic review and meta-analysis of randomised trials of cinnamon, fennel and ginger; nine studies with 647 patients.
Outcome, abstract wording for ginger: “ginger vs. placebo: WMD = 2.902, 95% CI = 2.039-3.765”. The abstract states that “pain intensity was significantly relieved in the trial group” for the herbal interventions, and that “Pain duration was significantly shorter in the trial group” for cinnamon.

Ginger and stretching exercises, primary dysmenorrhoea: PMID 28659234 (2017, randomised trial)

Design and population: randomised controlled trial of female students with moderate to severe primary dysmenorrhoea. 61 students in each group.
Dose and form: “250 mg ginger capsules from the onset of menstruation”. The comparator was stretching exercises, not placebo.
Outcome, abstract wording: “Exercise was significantly more effective than ginger for pain relief (31.57 ± 16.03 vs 38.19 ± 20.47, P = 0.02)”.

Ginger and Novafen, menstrual pain: PMID 30545531 (2018, crossover trial)

Design and population: crossover clinical trial of 168 single female students aged 18 to 26 with primary menstrual pain.
Dose and form: “200 mg capsule was given every 6 h for two serial cycles” of ginger or Novafen.
Outcome, abstract wording: “Differences between two groups each time showed no statistical significance (p > 0.05).” The abstract also reports that “the intensity of pain from dysmenorrhea decreased in the Novafen and Ginger groups.”

Ginger capsules, primary dysmenorrhoea: PMID 23865123 (2013, randomised trial)

Design and population: randomised trial of 70 female university students with primary dysmenorrhoea, divided into two equal groups.
Dose and form: ginger “in capsule form” against placebo.
Duration: 3 days in the first menstrual cycle.
Outcome, abstract wording: “the decrease in the visual analogue scores of post-therapy pain in the ginger group was significantly greater than that for placebo group. In the ginger group, 29 (82.85%) subjects reported an improvement in nausea symptoms, compared with 16 (47.05%) in the placebo group.”

Ginger and mefenamic acid, primary dysmenorrhoea: PMID 25399316 (2015, randomised trial)

Design and population: randomised clinical trial of 122 female students with moderate to severe primary dysmenorrhoea.
Dose and form: “250 mg capsules (zintoma) every 6 h from the onset of menstruation until pain relief lasted 2 cycles”. The comparator was mefenamic acid.
Outcome, abstract wording: “Repeated measurement showed a significant difference in pain intensity within the groups by time, but not between groups.” The abstract also reports that “The menstrual days were more in the ginger group in the first (p = 0.01) and second cycle (p = 0.04).”

Ginger and zinc sulfate, primary dysmenorrhoea: PMID 24559600 (2014, randomised trial)

Design and population: placebo-controlled randomised trial of 150 high school students, in three groups (ginger, zinc sulfate, placebo).
Dose and form: ginger capsules.
Duration: four days, from the day before menstruation to the third day of bleeding.
Outcome, abstract wording: “Compared with the placebo receiving group, participants receiving ginger and zinc sulfate reported more alleviation of pain during the intervention (p < .05).”

Weight and metabolic profile, overweight and obese adults: PMID 29393665 (2019, meta-analysis)

Design and population: systematic review and meta-analysis of 14 randomised trials with 473 subjects who were overweight or obese.
Outcome, abstract wording: “the supplementation with ginger significantly decreased body weight (BW) (SMD -0.66; 95% CI, -1.31, -0.01; P = 0.04), waist-to-hip ratio (WHR) (SMD -0.49…), hip ratio (HR) (SMD -0.42…), fasting glucose (SMD -0.68…) and insulin resistance index (HOMA-IR) (SMD -1.67…), and significantly increased HDL-cholesterol levels (SMD 0.40…)”. The abstract states that ginger “did not affect insulin, BMI, triglycerides, total- and LDL-cholesterol levels.”

Glycaemic control, blood pressure and lipids in type 2 diabetes: PMID 42337792 (2026, meta-analysis)

Design and population: meta-analysis of 13 articles of randomised trials comparing ginger with placebo in patients with type 2 diabetes.
Outcome, abstract wording: “Ginger supplementation was associated with a statistically significant reduction in fasting blood sugar (FBS) (MD -16.27 mg/dl, 95% CI (-25.75, -6.80), I2 = 86.39%), hemoglobin A1c (HbA1c) (MD -0.41%, 95% CI (-0.63, -0.20), I2 = 92.09%) systolic blood pressure (MD -1.62…), and triglyceride level (MD -17.10 mg/dL…); however, the magnitude of these effects was of limited clinical importance.” The abstract reports that treatment “did not significantly change homeostasis model assessment for insulin resistance (HOMAIR), diastolic blood pressure, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and body mass index (BMI).”

Thermic effect of food, healthy women: PMID 33487261 (2021, crossover randomised trial)

Design and population: randomised, double-masked, cross-over, placebo-controlled trial of 20 healthy eutrophic women, with a washout of at least seven days.
Dose and form: “two dry extract of ginger capsules (5% gingerol) or a placebo (cellulose)”, with a standardised breakfast.
Outcome, abstract wording: “Ginger intake did not increase the TEF of a standardized breakfast compared to the placebo. Oxygen consumption, respiratory quotient, blood pressure, heart rate, axillary temperature and metabolic profile were not different as well.”

Ginger on human health, 109 trials: PMID 31935866 (2020, systematic review)

Design and population: systematic review of 109 randomised controlled trials of ginger in all reported areas, under PRISMA.
Outcome, abstract wording: “Nevertheless, only 43 clinical trials (39.4%) met the criterion of having a ‘high quality of evidence.’ In addition to the quality assessment result, small populations and unstandardized evaluation systems were the observed shortcomings in ginger clinical trials.”

Umbrella review of oral ginger: PMID 35147170 (2022)

Design and population: umbrella review of 24 systematic reviews of orally consumed ginger.
Dose: “dosage of 0.5-3 g/d in capsule form administered for up to 3 mo was consistently reported as effective.” The abstract adds that “There was substantial heterogeneity and poor reporting of interventions”.
Outcome, abstract wording: “The strongest evidence was found for the antiemetic effects of ginger in pregnant women (effect size: large; GRADE: high), analgesic effects for osteoarthritis (effect size: small; GRADE: high), and glycemic control (effect size: none to very large; GRADE: very low to moderate).”

Evidence-quality assessment

Grade: B. At least one human randomised controlled trial is included, with material limits on size, duration and population. Grade A is not given: the included studies do not give consistent findings for the same outcome. They are positive for some outcomes and negative or mixed for others.

  • Consistency: positive results appear for chemotherapy-induced nausea quality of life (PMID 37699474), pregnancy nausea (PMIDs 24642205, 31937153), knee pain responders (PMID 11710709) and the knee OA meta-analysis (PMID 25300574), dysmenorrhoea pain (PMIDs 38770631, 26177393), metabolic meta-analyses (PMIDs 29393665, 42337792) and joint pain (PMID 40732990). Negative or mixed results appear for knee OA (PMIDs 10607493, 23964445, 32214292, and 14609531 in its first three months), for vomiting in pregnancy (PMID 31937153), for the thermic effect of food (PMID 33487261), and in dysmenorrhoea comparisons: the abstract of PMID 28659234 reports exercise as significantly more effective than ginger, and the abstract of PMID 25399316 reports no significant difference between ginger and mefenamic acid.
  • Study design: the evidence includes randomised trials and meta-analyses. Several meta-analyses report high heterogeneity: I2 of 81.05% (PMID 38770631), 86.39% (PMID 42337792) and 92.09% for HbA1c (PMID 42337792). The 2016 Cochrane review of dietary supplements for dysmenorrhoea judged all the evidence, across every supplement it assessed, low or very low quality (PMID 27000311). The 2015 osteoarthritis meta-analysis judged the evidence “of moderate quality” (PMID 25300574). The 2020 systematic review of 109 trials reports 43 trials (39.4%) as high quality (PMID 31935866).
  • Size: the largest single trial in this set is the 2001 knee osteoarthritis trial, 261 enrolled and 247 evaluable (PMID 11710709). The largest ginger nausea trial has 103 participants (PMID 37699474). Several trials have 20 to 30 participants (PMIDs 33487261, 14609531, 40732990).
  • Directness to a ginger extract powder: The preparations differ: standardised capsules stated as “84 mg/day active gingerols/shogaols” (PMID 37699474); an extract “standardized to contain 10% total gingerols and no more than 3% total shogaols” (PMID 40732990); “5% gingerol” capsules (PMID 33487261); an extract of Zingiber officinale with Alpinia galanga (PMID 11710709); a steamed extract GGE03 (PMID 39212491); and powdered ginger (PMID 23964445). The trial evidence therefore transfers only in part to the ginger extract powder named in the disclosure.
  • Transfer to population and format: the outcomes were tested in chemotherapy patients, pregnant women, adults with knee osteoarthritis, students with dysmenorrhoea, healthy adults, women with eutrophic status and adults with type 2 diabetes. Results from one group do not transfer directly to the others.

Mixed evidence on osteoarthritis. The umbrella review rates the analgesic effect of ginger in osteoarthritis as “GRADE: high” (PMID 35147170). The 2020 meta-analysis concludes that “There is insufficient evidence to support the use of oral ginger compared with placebo” (PMID 32214292).

Limitations

Records were assessed from their published abstracts rather than from full texts.

  • Several abstracts do not state the dose, the form or the marker used, including PMIDs 10607493, 23865123, 24559600 and 27000311.
  • The 2020 systematic review (PMID 32214292) pairs a 95% CI of “-4.30 to -1.09” with P = 0.24, which is internally inconsistent. The figures are reported as printed.
  • The 2001 knee osteoarthritis extract (PMID 11710709) contained a second species, Alpinia galanga, and is not an extract of Zingiber officinale alone.
  • The outcomes and the populations differ between trials.
  • No included trial reports a 6-gingerol content or tests a 6-gingerol-standardised product.
  • The search used six PubMed search strings. No trial registries, grey literature or full-text risk-of-bias assessment were used.

Conclusion

By outcome, the included records answer the question in both directions. For nausea, one 2024 trial reports results favouring ginger for nausea-related quality of life and delayed nausea severity (PMID 37699474). A 2019 meta-analysis reports an odds ratio of 0.71 for ginger in controlling CINV, and that ginger could only reduce acute CINV (PMID 30299420). In pregnancy, PMID 24642205 reports that ginger significantly improved the symptoms of nausea when compared to placebo, and PMID 31937153 reports a significant effect on nausea severity against placebo but not on vomiting. The 2023 meta-analysis PMID 36969661 reports, for ginger, a higher effective rate than placebo and also the same antiemetic effect as placebo.

For knee osteoarthritis and joint pain, one 2001 trial reports a superior responder rate for knee pain on standing in the ginger extract group (PMID 11710709), a 2015 meta-analysis reports a statistically significant pain reduction in favor of ginger (PMID 25300574), and a gonarthritis crossover trial reports that the ginger extract was as effective as placebo during the first 3 months and showed a significant superiority over placebo at the end of 6 months (PMID 14609531). In the other direction, a 2012 trial reports that one gram of powdered ginger per day did not improve knee joint pain (PMID 23964445), a crossover trial reports that no significant difference between placebo and ginger extract could be demonstrated (PMID 10607493), and a 2020 meta-analysis reports that there is insufficient evidence to support the use of oral ginger compared with placebo (PMID 32214292). A 2025 randomised trial reports improved ratings of pain, stiffness, and functional capacity (PMID 40732990).

For primary dysmenorrhoea, PMID 38770631 reports that ginger is notably more effective than placebo in reducing both the intensity and duration of pain, PMID 26177393 reports a significant effect of ginger in reducing PVAS, and two placebo-controlled trials report greater alleviation of pain than placebo in the ginger groups (PMIDs 23865123, 24559600). Comparisons with other treatments report the following: PMID 28659234 reports that exercise was significantly more effective than ginger for pain relief; PMID 30545531 reports no statistical significance between the ginger and Novafen groups; and PMID 25399316 reports no significant difference in pain intensity between the groups. The 2016 Cochrane review of dietary supplements for dysmenorrhoea, in which ginger is one of the supplements assessed, judged all the evidence to be of low or very low quality (PMID 27000311).

For metabolic outcomes, PMID 29393665 reports that ginger significantly decreased body weight and fasting glucose, while PMID 42337792 reports that ginger may probably improve the metabolic indices, with effects of limited clinical importance. PMID 33487261 reports that ginger intake did not increase the TEF of a standardized breakfast compared to the placebo.

The record does not support a consistent effect across outcomes.

References

  1. Crichton M, Marshall S, Isenring E, Lohning A, McCarthy AL, Molassiotis A, et al. Effect of a Standardized Ginger Root Powder Regimen on Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Double-Blind, Placebo-Controlled Randomized Trial. Journal of the Academy of Nutrition and Dietetics. 2024;124(3):313-330.e6. PMID: 37699474. doi:10.1016/j.jand.2023.09.003
  2. Chang WP, Peng YX. Does the Oral Administration of Ginger Reduce Chemotherapy-Induced Nausea and Vomiting?: A Meta-analysis of 10 Randomized Controlled Trials. Cancer nursing. 2019;42(6):E14-E23. PMID: 30299420. doi:10.1097/NCC.0000000000000648
  3. Viljoen E, Visser J, Koen N, Musekiwa A. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutrition journal. 2014;13:20. PMID: 24642205. doi:10.1186/1475-2891-13-20
  4. Hu Y, Amoah AN, Zhang H, Fu R, Qiu Y, Cao Y, et al. Effect of ginger in the treatment of nausea and vomiting compared with vitamin B6 and placebo during pregnancy: a meta-analysis. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2022;35(1):187-196. PMID: 31937153. doi:10.1080/14767058.2020.1712714
  5. Tan MY, Shu SH, Liu RL, Zhao Q. The efficacy and safety of complementary and alternative medicine in the treatment of nausea and vomiting during pregnancy: A systematic review and meta-analysis. Frontiers in public health. 2023;11:1108756. PMID: 36969661. doi:10.3389/fpubh.2023.1108756
  6. Altman RD, Marcussen KC. Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis and rheumatism. 2001;44(11):2531-8. PMID: 11710709. doi:10.1002/1529-0131(200111)44:11<2531::aid-art433>3.0.co;2-j
  7. Bliddal H, Rosetzsky A, Schlichting P, Weidner MS, Andersen LA, Ibfelt HH, et al. A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and cartilage. 2000;8(1):9-12. PMID: 10607493. doi:10.1053/joca.1999.0264
  8. Niempoog S, Pawa KK, Amatyakul C. The efficacy of powdered ginger in osteoarthritis of the knee. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2012;95 Suppl 1:S59-64. PubMed: 23964445
  9. Wigler I, Grotto I, Caspi D, Yaron M. The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis. Osteoarthritis and cartilage. 2003;11(11):783-9. PMID: 14609531. doi:10.1016/s1063-4584(03)00169-9
  10. Baek HI, Shen L, Ha KC, Park YK, Kim CS, Kwon JE, et al. Effectiveness and safety of steamed ginger extract on mild osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial. Food & function. 2024;15(18):9512-9523. PMID: 39212491. doi:10.1039/d4fo01640h
  11. Araya-Quintanilla F, Gutierrez-Espinoza H, Munoz-Yanez MJ, Sanchez-Montoya U, Lopez-Jeldes J. Effectiveness of Ginger on Pain and Function in Knee Osteoarthritis: A PRISMA Systematic Review and Meta-Analysis. Pain physician. 2020;23(2):E151-E161. PubMed: 32214292
  12. Bartels EM, Folmer VN, Bliddal H, Altman RD, Juhl C, Tarp S, et al. Efficacy and safety of ginger in osteoarthritis patients: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis and cartilage. 2015;23(1):13-21. PMID: 25300574. doi:10.1016/j.joca.2014.09.024
  13. Broeckel J, Estes L, Leonard M, Dickerson BL, Gonzalez DE, Purpura M, et al. Effects of Ginger Supplementation on Markers of Inflammation and Functional Capacity in Individuals with Mild to Moderate Joint Pain. Nutrients. 2025;17(14). PMID: 40732990. doi:10.3390/nu17142365
  14. Moshfeghinia R, Salmanpour N, Ghoshouni H, Gharedaghi H, Zare R, Cramer H, et al. Ginger for Pain Management in Primary Dysmenorrhea: A Systematic Review and Meta-Analysis. Journal of integrative and complementary medicine. 2024;30(11):1016-1030. PMID: 38770631. doi:10.1089/jicm.2023.0799
  15. Daily JW, Zhang X, Kim DS, Park S. Efficacy of Ginger for Alleviating the Symptoms of Primary Dysmenorrhea: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Pain medicine (Malden, Mass.). 2015;16(12):2243-55. PMID: 26177393. doi:10.1111/pme.12853
  1. Pattanittum P, Kunyanone N, Brown J, Sangkomkamhang US, Barnes J, Seyfoddin V, et al. Dietary supplements for dysmenorrhoea. The Cochrane database of systematic reviews. 2016;3(3):CD002124. PMID: 27000311. doi:10.1002/14651858.CD002124.pub2
  2. Xu Y, Yang Q, Wang X. Efficacy of herbal medicine (cinnamon/fennel/ginger) for primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials. The Journal of international medical research. 2020;48(6):300060520936179. PMID: 32603204. doi:10.1177/0300060520936179
  3. Shirvani MA, Motahari-Tabari N, Alipour A. Use of ginger versus stretching exercises for the treatment of primary dysmenorrhea: a randomized controlled trial. Journal of integrative medicine. 2017;15(4):295-301. PMID: 28659234. doi:10.1016/S2095-4964(17)60348-0
  4. Adib Rad H, Basirat Z, Bakouei F, Moghadamnia AA, Khafri S, Farhadi Kotenaei Z, et al. Effect of Ginger and Novafen on menstrual pain: A cross-over trial. Taiwanese journal of obstetrics & gynecology. 2018;57(6):806-809. PMID: 30545531. doi:10.1016/j.tjog.2018.10.006
  5. Jenabi E. The effect of ginger for relieving of primary dysmenorrhoea. JPMA. The Journal of the Pakistan Medical Association. 2013;63(1):8-10. PubMed: 23865123
  6. Shirvani MA, Motahari-Tabari N, Alipour A. The effect of mefenamic acid and ginger on pain relief in primary dysmenorrhea: a randomized clinical trial. Archives of gynecology and obstetrics. 2015;291(6):1277-81. PMID: 25399316. doi:10.1007/s00404-014-3548-2
  7. Kashefi F, Khajehei M, Tabatabaeichehr M, Alavinia M, Asili J. Comparison of the effect of ginger and zinc sulfate on primary dysmenorrhea: a placebo-controlled randomized trial. Pain management nursing : official journal of the American Society of Pain Management Nurses. 2014;15(4):826-33. PMID: 24559600. doi:10.1016/j.pmn.2013.09.001
  8. Maharlouei N, Tabrizi R, Lankarani KB, Rezaianzadeh A, Akbari M, Kolahdooz F, et al. The effects of ginger intake on weight loss and metabolic profiles among overweight and obese subjects: A systematic review and meta-analysis of randomized controlled trials. Critical reviews in food science and nutrition. 2019;59(11):1753-1766. PMID: 29393665. doi:10.1080/10408398.2018.1427044
  9. Chen X, Cheng S, Zhang D. Meta-analysis of the effects of ginger supplementation on glycemic control, blood pressure and lipid profile in patients with type 2 diabetes. Systematic reviews. 2026;15(1). PMID: 42337792. doi:10.1186/s13643-026-03251-5
  10. Fagundes GBP, Rodrigues AMDS, Martins LB, Monteze NM, Correia MITD, Teixeira AL, et al. Acute effects of dry extract of ginger on energy expenditure in eutrophic women: A randomized clinical trial. Clinical nutrition ESPEN. 2021;41:168-174. PMID: 33487261. doi:10.1016/j.clnesp.2020.10.001
  11. Anh NH, Kim SJ, Long NP, Min JE, Yoon YC, Lee EG, et al. Ginger on Human Health: A Comprehensive Systematic Review of 109 Randomized Controlled Trials. Nutrients. 2020;12(1). PMID: 31935866. doi:10.3390/nu12010157
  12. Crichton M, Davidson AR, Innerarity C, Marx W, Lohning A, Isenring E, et al. Orally consumed ginger and human health: an umbrella review. The American journal of clinical nutrition. 2022;115(6):1511-1527. PMID: 35147170. doi:10.1093/ajcn/nqac035

Disclosure of commercial interest

Bionutricia has a commercial interest in this subject. Bionutricia Extract’s product line lists “Ginger (Zingiber officinale) Standardized Extract Powder”. Its product page states the actives and standardisation as “Pure 100:1 Ginger (Zingiber officinale) Extract” and “0.1-0.2% 6-gingerol”. Bionutricia Extract, the ingredient-supply arm of the company, supplies this ingredient. bionutricia.com, the contract-manufacturing arm, manufactures finished formats.

The trial abstracts use other names for the same material: “ginger root powder”, “ginger extract”, “dried ginger powder” and “ginger capsules”. These are the same thing, the rhizome of Zingiber officinale, prepared in different forms. The preparations differ in process and standardisation, which the evidence-quality section addresses. One included trial (PMID 11710709) used an extract of Zingiber officinale together with Alpinia galanga, a different plant, and is not the same material as the product.

Its findings and its evidence grade were not altered to favour any product. Nothing in this review is medical advice, and nothing in it claims that any product treats, prevents or cures any condition.

Author biography

Vitthia Rama Murti, Registered Pharmacist (RPh 15632). Subject scope: formulation, excipients, stability, tolerability and safety; clinical evidence, including human trials, indications, dosing and clinical outcomes.

Ts. Ng Kuak Ping, Professional Technologist (MBOT). Subject scope: extraction, processing, standardisation, raw-material quality and manufacturing format. Co-signs the standardisation and specification content of this review.

Review history

  • Date written: 3 November 2026
  • Written by: Vitthia Rama Murti
  • Standardisation and specification content co-signed by: Ts. Ng Kuak Ping
  • Re-angled to an outcome-by-outcome question: 3 November 2026
  • Reviewed by: Dr Yong Yi Yi
  • Date reviewed: pending sign-off

See our ingredient line


Bionutricia Manufacturing Sdn Bhd (201001031866 / 915789-W) © 2026. All Rights Reserved.

Shopping cart

0
image/svg+xml

No products in the cart.

Continue Shopping